Feedback

Browsing by K


Use an asterisk (*) for partial word searches (e.g. pemph*)

24 results found.

1.
2.
Ordering Recommendation:   Confirm diagnosis of Kabuki syndrome; sequencing detects the majority of pathogenic mutations.
3.
4.
Ordering Recommendation:   Aids in the diagnosis of multiple myeloma and related disorders. Preferred test is the quantitative test (Kappa and Lambda Free Light Chains (Bence Jones Protein), Quantitative, Urine (0050618)).
5.
Ordering Recommendation:   Aids in the diagnosis and management of multiple myeloma and related disorders. Preferred test to detect and quantify urinary free light chains (Bence Jones protein).
6.
Ordering Recommendation:   Quantify and determine clonality of free kappa light chains (Bence Jones protein) in urine.
7.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
8.
9.
Ordering Recommendation:   Aids in the evaluation and management of multiple myeloma and related plasma cell disorders.
10.
11.
Ordering Recommendation:   Assess risk for alloimmune hemolytic disease of the newborn or hemolytic transfusion reaction. Test may be ordered for parental or fetal genotyping.
12.
13.
14.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
15.
16.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
17.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
18.
Ordering Recommendation:   Preferred test is urine supersaturation profile or urinary calculi risk assessment, depending on calculation need. May be used to monitor kidney stone formation. Panel includes calcium, citric acid, creatinine, oxalate, and uric acid.
19.
Ordering Recommendation:   Aids in the diagnosis of mastocytosis. Provide prognostic and predictive information for tyrosine kinase inhibitor (TKI) therapy planning.
20.
Ordering Recommendation:   Prognostication in core-binding factor-related (CBF) AML.
21.
Ordering Recommendation:   Predicts response to tyrosine kinase inhibitor (TKI) therapy.
22.
23.
Ordering Recommendation:   Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, colorectal and lung cancer).
24.
Ordering Recommendation:   Determine eligibility for anti-EGFR (cetuximab and panitumumab) therapy in patients with metastatic colorectal cancer.